Otsuka Multi-Tracer/Multi-Dose Study (snd_ro2)
What is the purpose of this trial?
You are invited to take part in a research study designed to evaluate the action of a new
investigational drug (a drug that has not been approved by the FDA), centanafadine. This drug is
designed to interact with serotonin (SERT), dopamine (DAT), and norepinephrine (NET)
transporters in the brain. A transporter is a protein in the brain that affects brain function. Many
medications are designed to reach and interact with transporters in your brain. Centanafadine is
being studied as a possible treatment for attention-deficit/hyperactivity disorder (ADHD).
We will be using an imaging technique called PET (Positron Emission Tomography) to
measure the interaction of centanafadine and the transporters in your brain. You will receive up
to 8 oral doses of centanafadine and up to five injections of radiotracer during this study. A
radiotracer is a low dose of a drug that has a radioactive marker attached to it, so that it can be
detected in the brain. The radiotracer gives off energy (gamma-rays) that is detected by the PET scanner to create brain images.
- Ages18 - 45 years
- GenderMale only
- Trial withOtsuka Pharmaceutical Development & Commercialization, Inc.
- Start Date03/26/2019
- End Date12/30/2019
- Last Updated07/24/2019
- Study HIC#2000023962